Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

Logos Global Management 13F Holdings (Q2 2026)

According to its SEC 13F filed on Aug 14, 2026, Logos Global Management reported 68 long positions worth $2.32B as of Jun 30, 2026. ERAS is 9.6% of the portfolio and the top 10 holdings are 48%. Against Q1 2026 it opened 26 new positions, added to 17, trimmed 19 and exited 24. 20 holdings have a dated FDA decision or data readout in the next 90 days, and 25 more expect one in a stated window such as "H2 2026".

Data as of Jun 30, 2026SEC 13F filed Aug 14, 2026Next filing (Q3 2026) due Nov 16, 2026Value as filed; options at underlying sharesLong positions only
Market Value$ 2.32 B13F value, as filed
QoQ Changes15.98 %13F value vs the previous quarter
Holdings68 68 stocks · 0 option positions
PeriodQ2 202613F reporting quarter
Holdings in Top 20 % top 10: 48% of the portfolio
Activity vs Q1 202626 new17 added · 19 trimmed · 24 exits
Catalysts ahead20dated in 90 days · +25 in a stated window

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 68. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
REPL
REPL
REPLIMUNE GROUP INC
2.50 M
27.68 M
1.2
New
Commercial
None in 90 days
RACC
RACC
RESEARCH ALLIANCE CORP III
100.00 K
1.07 M
0
New
—
None in 90 days
QTTB
QTTB
Q32 BIO INC
800.00 K
10.19 M
0.4
New
Clinical
Expected H2 2026
Phase 2a data readout
DFTX
DFTX
DEFINIUM THERAPEUTICS INC
80.00 K
3.76 M
0.2
New
Clinical
None in 90 days
QURE
QURE
UNIQURE NV
30.00 K
1.38 M
0.1
New
Clinical
None in 90 days
ERAS
ERAS
ERASCA INC
12.15 M
222.59 M
9.6
Added +9%
Clinical
Nov 20, 2026
Pre-clinical data presentation

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about Logos Global Management's 13F

What does Logos Global Management own?

68 stocks worth $2.32B at Jun 30, 2026, as reported in its 13F, led by ERAS (9.6% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q1 2026: 26 new positions, 17 increases, 19 reductions and 24 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by Logos Global Management LP, accession 0001172661-26-003529, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.